Photo: IS Global

Tim Wells highlights important elements of the PAMAfrica project

Tim Wells, MMV's Chief Scientific Officer, talks about the PAMAfrica project, an ambitious drug development programme that aims to develop new antimalarial medicines for the most at-risk populations, including newborns, patients with severe malaria and those with drug-resistant infections.

Led by MMV, the PAMAfrica Consortium, a group of nine public and private sector research partners across Africa and Europe, has been granted €21.9 million over 5 years by European & Developing Countries Clinical Trials Partnership (EDCTP) to implement this programme, with an additional €22m from MMV, Novartis and other partners.

Read the article here